Cerulean appoints Edward Garney CMO
This article was originally published in Scrip
Cerulean Pharma, a developer of tumour-targeted nanopharmaceuticals, has appointed Dr Edward Garney chief medical officer. Dr Garney previously served as vice-president for clinical development at ArQule, where he developed and oversaw clinical trials of its lead non-small cell lung cancer treatment, ARQ 197 (tivantinib).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.